keyword
MENU ▼
Read by QxMD icon Read
search

Zoledronic acid

keyword
https://www.readbyqxmd.com/read/28324132/erratum-to-cost-effectiveness-analysis-of-once-yearly-injection-of-zoledronic-acid-for-the-treatment-of-osteoporosis-in-japan
#1
K Moriwaki, M Mouri, H Hagino
No abstract text is available yet for this article.
March 21, 2017: Osteoporosis International
https://www.readbyqxmd.com/read/28318924/aged-rats-under-zoledronic-acid-therapy-and-oral-surgery
#2
Mariza Akemi Matsumoto, Elisa Mara de Abreu Furquim, Alaíde Gonçalves, Joel Ferreira Santiago-Júnior, Patrícia Pinto Saraiva, Camila Lopes Cardoso, Marcelo Salles Munerato, Roberta Okamoto
INTRODUCTION: Aging brings a number of health conditions that can compromise the healing process in elderly individuals, significantly when it comes to bone tissue. The aim of the present study was to analyze the effects of zoledronic acid (ZL) therapy on socket healing of aged male rats. MATERIALS AND METHODS: Twenty-four Wistar male rats, 20 months old, underwent surgical procedures for the extraction of the upper right incisor and were divided into two groups according to the treatment: Control (C) - intravenous (IV) 0...
February 17, 2017: Journal of Cranio-maxillo-facial Surgery
https://www.readbyqxmd.com/read/28300506/adding-celecoxib-with-or-without-zoledronic-acid-for-hormone-na%C3%A3-ve-prostate-cancer-long-term-survival-results-from-an-adaptive-multiarm-multistage-platform-randomized-controlled-trial
#3
Malcolm D Mason, Noel W Clarke, Nicholas D James, David P Dearnaley, Melissa R Spears, Alastair W S Ritchie, Gerhardt Attard, William Cross, Rob J Jones, Christopher C Parker, J Martin Russell, George N Thalmann, Francesca Schiavone, Estelle Cassoly, David Matheson, Robin Millman, Cyrill A Rentsch, Jim Barber, Clare Gilson, Azman Ibrahim, John Logue, Anna Lydon, Ashok D Nikapota, Joe M O'Sullivan, Emilio Porfiri, Andrew Protheroe, Narayanan Nair Srihari, David Tsang, John Wagstaff, Jan Wallace, Catherine Walmsley, Mahesh K B Parmar, Matthew R Sydes
Purpose Systemic Therapy for Advanced or Metastatic Prostate Cancer: Evaluation of Drug Efficacy is a randomized controlled trial using a multiarm, multistage, platform design. It recruits men with high-risk, locally advanced or metastatic prostate cancer who were initiating long-term hormone therapy. We report survival data for two celecoxib (Cel)-containing comparisons, which stopped accrual early at interim analysis on the basis of failure-free survival. Patients and Methods Standard of care (SOC) was hormone therapy continuously (metastatic) or for ≥ 2 years (nonmetastatic); prostate (± pelvic node) radiotherapy was encouraged for men without metastases...
March 13, 2017: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/28289967/a-pilot-trial-evaluating-zoledronic-acid-induced-changes-in-18-f-fmau-positron-emission-tomography-imaging-of-bone-metastases-in-prostate-cancer
#4
Ulka N Vaishampayan, Omid S Tehrani, Jawana M Lawhorn-Crews, Lance K Heilbrun, Kimberlee Dobson, Daryn Smith, Brenda Dickow, Anthony F Shields
PURPOSE: We conducted a pilot trial utilizing [(18)F]FMAU [1-(2'-deoxy-2'-[(18)F]fluoro-β-D-arabinofuranosyl thymine] as a tumor tracer in positron emission tomography (PET) and evaluated its reproducibility, and changes in maximum and peak standardized uptake value (SUVmax and SUVpeak) with zoledronic acid treatment in castrate resistant prostate cancer (CRPC) patients with bone metastases (BM). PROCEDURES: Eligible patients had CRPC with radiographic evidence of BM and creatinine clearance >30 ml/min...
March 13, 2017: Molecular Imaging and Biology: MIB: the Official Publication of the Academy of Molecular Imaging
https://www.readbyqxmd.com/read/28287351/zoledronic-acid-treatment-in-primary-bone-marrow-edema-syndrome
#5
Bryan Josué Flores-Robles, Jesus Sanz-Sanz, Adel Abel Sanabria-Sanchinel, Dixie Huntley-Pascual, José Luis Andréu Sánchez, José Campos Esteban, Ricardo Blanco, Carolina Merino-Argumanez, Maria Espinosa-Malpartida, Maria Consuleo Ramos-Giráldez, Hildegarde Godoy-Tundidor, Maria Mercedes Jiménez-Palop, Carmen Barbadillo Mateos, Luis Fernando Villa-Alcázar, Carlos Maria Isasi, Juan Bartolome Mulero
Primary bone marrow edema syndrome (BMES) is characterized by the combination of joint pain and distinctive magnetic resonance imaging changes. It has been suggested that the use of bisphosphonate drugs reduce symptom severity. Our objective was to review cases of patients diagnosed with BMES in the last 7 years who had been treated with zoledronic acid. Access to a pharmaceutical database was gained in order to obtain a list of zoledronic acid prescriptions. Based on clinical and MRI criteria for BMES, patients were selected...
March 2017: Journal of Pain & Palliative Care Pharmacotherapy
https://www.readbyqxmd.com/read/28286299/importance-of-prompt-antiresorptive-therapy-in-postmenopausal-women-discontinuing-teriparatide-or-denosumab-the-denosumab-and-teriparatide-follow-up-study-data-follow-up
#6
Benjamin Z Leder, Joy N Tsai, Linda A Jiang, Hang Lee
When teriparatide and denosumab are discontinued, bone mineral density (BMD) abruptly decreases. To compare rates of bone loss in postmenopausal women who discontinue denosumab or teriparatide and receive no additional prescription osteoporosis medications to women who discontinue these drugs followed by prompt antiresorptive therapy, we asked women concluding the Denosumab and Teriparatide Administration (DATA) study and its extension, DATA-Switch, to return for BMD measurements 1-2years after study completion...
March 9, 2017: Bone
https://www.readbyqxmd.com/read/28284745/prolonged-use-of-zoledronic-acid-4-years-did-not-improve-outcome-in-multiple-myeloma-patients
#7
Agustin Avilès, Maria-Jesùs Nambo, Judith Huerta-Guzmàn, Sergio Cleto, Natividad Neri
BACKGROUND: Bisphosphonates, especially zoledronic acid (ZA), show antitumor effects in multiple myeloma (MM) and other neoplasms. The standard time for ZA administration has been 2 years. However, with improvement in overall survival (OS) in MM with new agents, it unclear whether ZA could be administered for a prolonged time to improve OS. PATIENTS AND METHODS: A total of 170 patients with untreated, symptomatic MM were randomly divided into a group to receive ZA for 4 years, with a control group to receive ZA for 2 years...
February 16, 2017: Clinical Lymphoma, Myeloma & Leukemia
https://www.readbyqxmd.com/read/28281643/reactive-oxygen-species-are-required-for-zoledronic-acid-induced-apoptosis-in-osteoclast-precursors-and-mature-osteoclast-like-cells
#8
Ta-Wei Tai, Ching-Yu Chen, Fong-Chin Su, Yuan-Kun Tu, Tsung-Ting Tsai, Chiou-Feng Lin, I-Ming Jou
Inhibiting osteoclasts and osteoclast precursors to reduce bone resorption is an important strategy to treat osteoclast-related diseases, such as osteoporosis, inflammatory bone loss, and malignant bone metastasis. However, the mechanism by which apoptosis is induced in the osteoclasts and their precursors are not completely understood. Here, we used nitrogen-containing bisphosphonate zoledronic acid (ZA) to induce cell apoptosis in human and murine osteoclast precursors and mature osteoclast-like cells. Caspase-3-mediated cell apoptosis occurred following the ZA (100 μM) treatment...
March 10, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28276638/intravenous-zoledronic-acid-5%C3%A2-mg-on-bone-turnover-markers-and-bone-mineral-density-in-east-china-subjects-with-newly-diagnosed-osteoporosis-a-24-month-clinical-study
#9
Bo-Cheng Liang, Zhen-Yu Shi, Bo Wang, Peng Wu, Ling-Cheng Kong, Jian-Liang Yao, Chun-Wen Li, Xiao-Lin Shi
OBJECTIVE: This randomized, double-blind, placebo-controlled study assessed the necessity of early intervention, safety and efficacy of intravenous zoledronic acid 5 mg/year in East China women with newly diagnosed osteoporosis at high risk of fracture during a 24-month treatment period. METHODS: Subjects (57 [52-62] years old) were randomized 3:2 to zoledronic acid versus placebo (randomized at baseline, zoledronic acid [175 cases], placebo-zoledronic acid [110 cases])...
March 9, 2017: Orthopaedic Surgery
https://www.readbyqxmd.com/read/28270269/retained-skeletal-effects-of-zoledronic-acid-following-discontinuation-of-treatment-a-review-of-the-literature
#10
Crystal M Deas, Pilar Murphy, Maryam Iranikhah, Maisha Kelly Freeman
OBJECTIVE: To evaluate the effects on bone mineral density (BMD), bone turnover markers (BTMs), and fracture incidence following zoledronic acid (ZOL) discontinuation. DATA SOURCES: A search of PubMed (1966-May 2016) and International Pharmaceutical Abstracts (1970-May 2016) was conducted using the MeSH terms zoledronic acid, osteoporosis, and withholding treatment. Free text searches included drug holiday and drug discontinuation. STUDY SELECTION AND DATA EXTRACTION: An initial review yielded 87 articles...
March 1, 2017: Consultant Pharmacist: the Journal of the American Society of Consultant Pharmacists
https://www.readbyqxmd.com/read/28265718/cost-effectiveness-analysis-of-once-yearly-injection-of-zoledronic-acid-for-the-treatment-of-osteoporosis-in-japan
#11
K Moriwaki, M Mouri, H Hagino
Model-based economic evaluation was performed to assess the cost-effectiveness of zoledronic acid. Although zoledronic acid was dominated by alendronate, the incremental quality-adjusted life year (QALY) was quite small in extent. Considering the advantage of once-yearly injection of zoledronic acid in persistence, zoledronic acid might be a cost-effective treatment option compared to once-weekly oral alendronate. INTRODUCTION: The purpose of this study was to estimate the cost-effectiveness of once-yearly injection of zoledronic acid for the treatment of osteoporosis in Japan...
March 6, 2017: Osteoporosis International
https://www.readbyqxmd.com/read/28264701/zoledronic-acid-alters-hematopoiesis-and-generates-breast-tumor-suppressive-bone-marrow-cells
#12
Jessalyn M Ubellacker, Marie-Therese Haider, Molly J DeCristo, Gloria Allocca, Nicola J Brown, Daniel P Silver, Ingunn Holen, Sandra S McAllister
BACKGROUND: The bone-targeting agent zoledronic acid (ZOL) increases breast cancer survival in subsets of patients, but the underlying reasons for this protective effect are unknown. ZOL modulates the activity of osteoclasts and osteoblasts, which form hematopoietic stem cell niches, and therefore may affect hematopoietic cells that play a role in breast cancer progression. METHOD: Immunocompetent and immunocompromised strains of mice commonly used for breast cancer research were injected with a single, clinically relevant dose of ZOL (100 μg/kg) or vehicle control...
March 6, 2017: Breast Cancer Research: BCR
https://www.readbyqxmd.com/read/28254863/bone-pain-induced-by-multiple-myeloma-is-reduced-by-targeting-v-atpase-and-asic3
#13
Masahiro Hiasa, Tatsuo Okui, Yohance M Allette, Matthew S Ripsch, Ge-Hong Sun-Wada, Hiroki Wakabayashi, G David Roodman, Fletcher A White, Toshiyuki Yoneda
Multiple myeloma patients experience severe bone pain (MMBP) that is undertreated and poorly understood. In this study, we studied MMBP in an intratibial mouse xenograft model that employs JJN3 human multiple myeloma cells. In this model, mice develop MMBP associated in bone with increased sprouting of calcitonin gene-related peptide-positive (CGRP(+)) sensory nerves and in dorsal root ganglia (DRG) with upregulation of phosphorylated ERK1/2 (pERK1/2) and pCREB, two molecular indicators of neuron excitation...
March 15, 2017: Cancer Research
https://www.readbyqxmd.com/read/28253589/-effect-of-zoledronate-on-protein-interaction-between-ca-2-calmodulin-dependent-protein-kinase%C3%A2-and-calmodulin-and-expression-of-downstream-genes-during-osteoclast-differentiation
#14
H Wang, W Dong, M C Qi, H Sun, X J Feng, L M Wen
Objective: To investigate the effect of zoledronate on protein interaction between Ca(2+)/calmodulin-dependent protein kinaseⅡ(CaMKⅡ) and calmodulin and protein expression of nuclear factor of activation of T cells-1 (NFATc1) and tartrate resistant acid phosphatase (TRAP) during osteoclast differentiation. Methods: Mouse RAW264.7 cells were divided into group A and B and were cultured. Group A was induced with 50 mg/L receptor activator of NF-κB ligand (RANKL) for osteoclastogenesis, and group B was treated with 1×10(-6) zoledronate for two days from day 2...
February 9, 2017: Zhonghua Kou Qiang Yi Xue za Zhi, Zhonghua Kouqiang Yixue Zazhi, Chinese Journal of Stomatology
https://www.readbyqxmd.com/read/28252282/reverse-microemulsion-based-synthesis-of-bis-phosphonate-metal-materials-with-controllable-physical-properties-an-example-using-zoledronic-acid-calcium-complexes
#15
Xu Li, Youssef W Naguib, Solange Valdes, Stephanie Hufnagel, Zhengrong Cui
The development of phosphonate-metal materials is tightly related to the advancement in their synthesis methods. Herein, using zoledronic acid (Zol), a bisphosphonate (bioacitve phosphonate with a 'P-C-P' structure), and calcium as model molecules, we applied the reverse microemulsion (RM) to synthesize a series of Zol-Ca complexes. We comprehensively i) studied the relationship between RM conditions, including the component ratio of RM, co-surfactants, reaction time, reactant concentrations, reaction temperature, and the presence of a phospholipid, 1, 2-dioleoyl-sn-glycero-3-phosphate acid (DOPA), and the physical properties of the complexes synthesized (i...
March 2, 2017: ACS Applied Materials & Interfaces
https://www.readbyqxmd.com/read/28251108/effect-of-zoledronic-acid-on-fracture-healing-in-osteoporotic-patients-with-intertrochanteric-fractures
#16
Prabhnoor Singh Hayer, Anit Kumar Samuel Deane, Atul Agrawal, Rajesh Maheshwari, Anil Juyal
AIMS: To assess the effect of zoledronic acid (ZOL) on fracture healing in osteoporotic patients with intertrochanteric fracture based on radiological evaluation and to study the correlations between severity of osteoporosis, age, gender, and time taken to fracture union. SETTINGS AND DESIGN: An open label study was conducted on 43 patients at a tertiary care center. SUBJECTS AND METHODS: The osteoporosis status of all the included patients was documented using a double-energy X-ray absorptiometry scan...
January 2017: International Journal of Applied and Basic Medical Research
https://www.readbyqxmd.com/read/28243883/two-year-persistence-and-compliance-with-osteoporosis-therapies-among-postmenopausal-women-in-a-commercially-insured-population-in-the-united-states
#17
Emily Durden, Lionel Pinto, Lorena Lopez-Gonzalez, Paul Juneau, Richard Barron
This retrospective, observational study assessed 2-year persistence and compliance by treatment, route of administration, and dosing frequency in postmenopausal women initiating a new osteoporosis therapy. Two-year persistence and compliance rates were higher in women receiving injectables compared with oral agents. PURPOSE: This study extends previous studies limited to 1-year follow-up by examining persistence with osteoporosis therapies over a 2-year period and compares short- and long-term trends in persistence and compliance among postmenopausal women with commercial or Medicare supplemental insurance in the USA...
December 2017: Archives of Osteoporosis
https://www.readbyqxmd.com/read/28239141/chronic-myeloid-leukemia-associated-hypercalcemia-a-case-report-and-literature-review
#18
REVIEW
David Toro-Tobón, Sarimar Agosto, Sara Ahmadi, Maureen Koops, Jan M Bruder
BACKGROUND Hypercalcemia associated with chronic myeloid leukemia (CML) is an ominous sign. Although rare, several cases have been reported and multiple pathophysiologic mechanisms have been independently proposed. We present a patient case and a literature review of the clinical presentation and mechanisms of CML-associated hypercalcemia. CASE REPORT A 58-year-old male with a past medical history of CML diagnosed six years earlier, presented to the emergency department with one week of acute confusion, disorientation, polyuria, and polydipsia...
February 27, 2017: American Journal of Case Reports
https://www.readbyqxmd.com/read/28230589/effects-of-local-and-systemic-zoledronic-acid-application-on-titanium-implant-osseointegration-an-experimental-study-conducted-on-two-surface-types
#19
Serkan Dundar, Ferhan Yaman, Orhan Gecor, Omer Cakmak, Mustafa Kirtay, Tuba Talo Yildirim, Tahir Karaman, Mehmet Emre Benlidayi
The aim of this study was to evaluate the effects of local and systemic zoledronic acid (ZA) applications on titaniumoksit ceramic blasted (TiO-CB)- and sandblasted large acid-grit (SLA)-surfaced titanium implant osseointegration. Twelve New Zealand White rabbits were used in the study, divided into 6 groups: the TiO-CB (TiO-CB-CNT) (n = 2) and SLA (SLA-CNT) (n = 2) control groups in which TiO-CB- and SLA-surfaced titanium implants were surgically inserted into rabbit tibias but no treatment was applied; the TiO-CB (TiO-CB-LZA) (n = 2) and SLA (SLA-LZA) (n = 2) local ZA groups in which 1 mL of normal saline solution containing 2 mg of ZA was injected into sockets and after this the implants were integrated; and the TiO-CB (TiO-CB-SZA) (n = 2) and SLA (SLA-SZA) (n = 2) systemic ZA groups in which a single infusion of 0...
February 22, 2017: Journal of Craniofacial Surgery
https://www.readbyqxmd.com/read/28223674/-a-case-of-recurrent-breast-cancer-with-bone-metastasis-successfully-treated-with-everolimus-and-exemestane-therapy
#20
Hidefumi Kubo, Yuta Kimura, Toru Kawaoka, Makoto Miyahara, Ryouichi Shimizu, Yukiko Nagashima, Shigeru Yamamoto, Hiroaki Nagano
We report a case of a patient treated with everolimus and exemestane combination therapy for bone metastasis after breast surgery.The patient, a 58-year-old woman, consulted our department for back pain in October 2014.S he was diagnosed with left breast cancer when she was 41 years old.She had received Bt+Ax for left breast cancer and administered tamoxifen for 5 years.We decided on everolimus and exemestane combination therapy after observing an abnormal uptake in the 7th to 8th thoracic vertebrae on a PET-CT scan...
February 2017: Gan to Kagaku Ryoho. Cancer & Chemotherapy
keyword
keyword
27337
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"